The FDA announced on April 13, 2015, that Hospira Inc. is recalling Ketorolac Tromethamine Injection due to crystallization. The recall affects specific lots distributed nationwide, in Puerto Rico and Guam.
How to tell if you have it
- Brand: Hospira
- Product: Ketorolac Tromethamine Injection
- NDC 00409-3795-01 (Hospira label)
- NDC 00409-3795-49 (NOVAPLUS label)
- Lots: 35-231-DK, 35-235-DK, 35-507-DK (Exp. 1NOV2015); 36-136-DK (Exp. 1DEC2015); 37-146-DK (Exp. 1JAN2016); 38-138-DK (Exp. 1FEB2016); 39-103-DK, 39-255-DK (Exp. 1MAR2016); 40-539-DK, 40-549-DK (Exp. 1APR2016); 41-079-DK (Exp. 1MAY2016); 42-252-DK, 42-254-DK (Exp. 1JUN2016); 43-262-DK, 43-263-DK (Exp. 1JUL2016); 45-031-DK, 45-032-DK, 45-033-DK (Exp. 1SEP2016); 46-001-DK (Exp. 1OCT2016)
- NOVAPLUS Lots: 35-230-DK (Exp. 1NOV2015); 40-535-DK (Exp. 1APR2016)
The hazard
The product may contain crystals, which poses a risk if injected. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show Hospira Inc. has 108 other recalls on record since April 5, 2012. Other recent recalls of similar products include Par Health Recalls Buprenorphine Injections Due to Crystallization (Sept. 8, 2026) and Rising Pharma Recalls Cyproheptadine Syrup Due to Crystallization (July 13, 2026).